Hypoxia and vascular endothelial growth factor stimulate angiogenic integrin expression in bovine retinal microvascular endothelial cells

Investigative Ophthalmology and Visual Science

Volumn 39, Issue 6, 1998, Pages 1028-1035

  Suzuma, Kiyoshi ^a   Takagi, Hitoshi ^a   Otani, Atsushi ^a   Honda, Yoshihito ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DIOXIDE; INTEGRIN; MESSENGER RNA; NEUTRALIZING ANTIBODY; NITROGEN; OXYGEN; RECOMBINANT VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CATTLE; CELL CULTURE; CELL HYPOXIA; CONTROLLED STUDY; ENDOTHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; RETINA CAPILLARY;

ANIMALS; ANTIGENS, CD; BLOTTING, NORTHERN; CATTLE; CELL HYPOXIA; CELLS, CULTURED; DNA PRIMERS; ELECTROPHORESIS, AGAR GEL; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; INTEGRIN ALPHAV; INTEGRINS; LYMPHOKINES; RECEPTORS, VITRONECTIN; RECOMBINANT PROTEINS; RETINAL VESSELS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0031976812     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
2. Berse B, Brown LF, Van-de-Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell. 1992;3:211-220.
3. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309.
4. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457-10461.
5. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LE. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA. 1996;93:4851-4856.
6. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66-71.
7. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103:1820-1828.
8. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders [see comments]. N Engl J Med. 1994;331: 1480-1487.
9. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
10. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol. 1996;80:241-245.
11. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Trans-differentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855-868.
12. Varner JA, Brooks PC, Cheresh DA. Review: the integrin αvβ3: angiogenesis and apoptosis. Cell Adhes Commun. 1995;3:367-374.
13. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11-25.
14. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin αvβ3 during angiogenesis. J Clin Invest. 1996;98: 426-433.
15. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the αvβ3 integrin, osteopontin, and thrombin. Am J Pathol. 1996;149:293-305.
16. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin [see comments]. J Clin Invest. 1995; 96:1815-1822.
17. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science. 1994;264:569-571.
18. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
19. Hammes HP, Brownlee M, Jonczyk A, Sutler A, Preissner KT. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrals inhibits retinal neovascularization. Nat Med. 1996;2:529-533.
20. Luna J, Tobe T, Mousa SA, Reilly TM, Campochiaro PA. Antagonists of integrin αvβ3 inhibit retinal neovascularization in a murine model. Lab Invest. 1996;75:563-573.
21. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct αv integrins. Science. 1995;270:1500-1502.
22. Friedlander M, Theesfeld CL, Sugita M, et al. Involvement of integrins αvβ3 and αvβ5 in ocular neovascular diseases. Proc Natl Acad Sci USA. 1996;93:9764-9769.
23. King GL, Goodman AD, Buzney S, Moses A, Kahn CR. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest. 1985;75:1028-1036.
24. Takagi H, King GL, Robinson GS, Ferrara N, Aiello LP. Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Invest Ophthalmol Vis Sci. 1996;37:2165-2176.
25. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction [see comments]. Science. 1992;257:967-971.
26. Suzuki S, Argraves WS, Pytela R, et al. cDNA and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin reveal a transmembrane domain and homologies with other adhesion protein receptors. Proc Natl Acad Sci USA. 1986;83: 8614-8618.
27. Argraves WS, Suzuki S, Arai H, Thompson K, Pierschbacher MD, Ruoslahti E. Amino acid sequence of the human fibronectin receptor. J Cell Biol. 1987;105:1183-1190.
28. Akiyama SK, Yamada KM. Biosynthesis and acquisition of biological activity of the fibronectin receptor. J Biol Chem. 1987;262: 17536-17542.
29. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993;7:1475-1482.
30. Rodan GA. Osteopontin overview. Ann N Y Acad Sci. 1995;760: 1-5.
31. Cheresh DA, Smith JW, Cooper HM, Quaranta V. A novel vitronectin receptor integrin (αvβx) is responsible for distinct adhesive properties of carcinoma cells. Cell. 1989;57:59-69.
32. Clyman RI, Mauray F, Kramer RH. β1 and β3 integrins have different roles in the adhesion and migration of vascular smooth muscle cells on extracellular matrix. Exp Cell Res. 1992;200:272-284.
33. Lawson MA, Maxfield FR. Ca(2+)- and calcineurin-dependent recycling of an integrin to the front of migrating neutrophils. Nature. 1995;376:75-79.
34. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes. 1995;44: 98-103.
35. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145:574-584.
36. Klein S, Giancotti FG, Presta M, Albelda SM, Buck CA, Rifkin DB. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol Biol Cell. 1993;4:973-982.
37. Lewis JM, Cheresh DA, Schwartz MA. Protein kinase C regulates αvβ5-dependent cytoskeletal associations and focal adhesion kinase phosphorylation. J Cell Biol. 1996;134:1323-1332.
38. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 1996;98: 2018-2026.
39. Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. Annu Rev Cell Biol. 1995;11: 549-599.
40. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;113:1558-1544.
41. Khaliq A, Patel B, Jarvis-Evans J, Moriarty P, McLeod D, Boulton M. Oxygen modulates production of bFGF and TGF-β by retinal cells in vitro. Exp Eye Res. 1995;60:415-423.
42. Shreeniwas R, Koga S, Karakurum M, et al. Hypoxia-mediated induction of endothelial cell interleukin-1α. An autocrine mecha-nism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest. 1992;90:2333-2339.
43. Ala Y, Palluy O, Favero J, Bonne C, Modat G, Dornand J. Hypoxia/ reoxygenation stimulates endothelial cells to promote interleukin-1 and interleukin-6 production. Effects of free radical scavengers. Agents Actions. 1992;37:134-139.
44. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest. 1996;98:1667-1675.
45. Brooks PC, Stromblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell. 1996;85:683-693.